Table 3.
Clinical and Imaging Characteristic Between Patients With and Without Composite Adverse Outcomes.
| Patients without composite adverse outcomes (n = 57) | Patients with composite adverse outcomes (n = 51) | p Value | |
|---|---|---|---|
| Age, years | 54 ± 13 | 57 ± 10 | 0.163 |
| Female | 8 | 12 | 0.205 |
| Body mass index, kg/m2 | 26.5 ± 3.1 | 26.3 ± 3.6 | 0.775 |
| Paroxysmal/Persistent AF | 37/20 | 22/29 | 0.023 |
| Duration of AF, months (median, IQR) | 24, 9–60 | 36, 5–84 | 0.709 |
| CHA2DS2-VaSc score | 1.0 ± 0.7 | 2.0 ± 1.5 | <0.001 |
| HFpEF/HFmrEF/HFrEF | 37/16/4 | 18/19/14 | 0.002 |
| Diabetes mellitus | 4 | 7 | 0.250 |
| Hypertension | 13 | 17 | 0.223 |
| LV EF, % | 54 ± 11 | 47 ± 12 | 0.001 |
| LA volume index, ml/m2 | 74.2 ± 22.5 | 96.4 ± 21.7 | <0.001 |
| SRe, s−1 | 91.6 ± 16.1 | 82.7 ± 15.5 | 0.005 |
| LGE, no. of patients | 16 | 23 | 0.066 |
| LV native T1 average, ms | 1274 ± 32 | 1321 ± 45 | <0.001 |
| LV ECV average, % | 26.8 ± 2.1 | 30.7 ± 3.6 | <0.001 |